GSK Net Profit Margin 2010-2023 | GSK
Current and historical net profit margin for GSK (GSK) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. GSK net profit margin for the three months ending March 31, 2023 was .
| GSK Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2023-03-31 |
$31.59B |
$17.89B |
56.63% |
| 2022-12-31 |
$36.27B |
$18.50B |
51.00% |
| 2022-09-30 |
$43.90B |
$16.61B |
37.84% |
| 2022-06-30 |
$47.19B |
$6.07B |
12.86% |
| 2022-03-31 |
$49.80B |
$6.97B |
13.99% |
| 2021-12-31 |
$46.91B |
$6.03B |
12.86% |
| 2021-09-30 |
$45.57B |
$6.00B |
13.17% |
| 2021-06-30 |
$44.22B |
$6.00B |
13.57% |
| 2021-03-31 |
$42.37B |
$6.86B |
16.18% |
| 2020-12-31 |
$43.78B |
$7.38B |
16.86% |
| 2020-09-30 |
$43.78B |
$8.12B |
18.54% |
| 2020-06-30 |
$44.19B |
$8.42B |
19.06% |
| 2020-03-31 |
$44.77B |
$6.86B |
15.31% |
| 2019-12-31 |
$43.10B |
$5.93B |
13.76% |
| 2019-09-30 |
$38.25B |
$5.56B |
14.53% |
| 2019-06-30 |
$37.22B |
$5.49B |
14.76% |
| 2019-03-31 |
$37.13B |
$4.85B |
13.07% |
| 2018-12-31 |
$41.14B |
$4.84B |
11.75% |
| 2018-09-30 |
$44.61B |
$2.83B |
6.35% |
| 2018-06-30 |
$44.33B |
$2.57B |
5.80% |
| 2018-03-31 |
$43.74B |
$1.74B |
3.98% |
| 2017-12-31 |
$38.90B |
$1.98B |
5.08% |
| 2017-09-30 |
$38.21B |
$2.97B |
7.78% |
| 2017-06-30 |
$37.84B |
$2.45B |
6.46% |
| 2017-03-31 |
$37.85B |
$2.05B |
5.42% |
| 2016-12-31 |
$37.63B |
$1.16B |
3.08% |
| 2016-09-30 |
$37.82B |
$0.30B |
0.79% |
| 2016-06-30 |
$37.41B |
$0.07B |
0.20% |
| 2016-03-31 |
$37.06B |
$0.93B |
2.50% |
| 2015-12-31 |
$36.65B |
$12.77B |
34.84% |
| 2015-09-30 |
$36.35B |
$14.87B |
40.90% |
| 2015-06-30 |
$35.97B |
$14.68B |
40.81% |
| 2015-03-31 |
$36.42B |
$15.57B |
42.74% |
| 2014-12-31 |
$37.35B |
$4.44B |
11.89% |
| 2014-09-30 |
$39.27B |
$6.81B |
17.34% |
| 2014-06-30 |
$40.67B |
$7.73B |
19.00% |
| 2014-03-31 |
$41.36B |
$8.22B |
19.87% |
| 2013-12-31 |
$41.79B |
$8.56B |
20.48% |
| 2013-09-30 |
$41.34B |
$6.01B |
14.53% |
| 2013-06-30 |
$41.34B |
$6.25B |
15.12% |
| 2013-03-31 |
$41.38B |
$6.62B |
16.01% |
| 2012-12-31 |
$42.22B |
$7.30B |
17.28% |
| 2012-09-30 |
$42.43B |
$7.90B |
18.62% |
| 2012-06-30 |
$43.22B |
$8.28B |
19.16% |
| 2012-03-31 |
$43.96B |
$8.10B |
18.43% |
| 2011-12-31 |
$43.79B |
$8.41B |
19.20% |
| 2011-09-30 |
$44.43B |
$5.32B |
11.97% |
| 2011-06-30 |
$43.69B |
$5.21B |
11.92% |
| 2011-03-31 |
$41.94B |
$2.98B |
7.11% |
| 2010-12-31 |
$42.68B |
$2.60B |
6.08% |
| 2010-09-30 |
$44.26B |
$6.44B |
14.54% |
| 2010-06-30 |
$44.80B |
$6.60B |
14.74% |
| 2010-03-31 |
$46.13B |
$9.29B |
20.15% |
| 2009-12-31 |
$44.58B |
$8.92B |
20.01% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$70.106B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
